ResMed files patent suit against Chinese vendor


By Dylan Bushell-Embling
Friday, 07 June, 2013

ResMed (ASX:RMD) has taken a Chinese medical device manufacturer to court, alleging infringement of its respiratory device patents.

ResMed has filed a patent infringement lawsuit in a California court against BMC Medical and its US sales subsidiary 3B Products.

The suit accuses the manufacturer of violating ResMed patents with two continuous positive airway pressure (CPAP) sleep-disordered breathing treatment devices, as well as two nasal products.

ResMed is also seeking to have BMC added to its pending International Trade Commission (ITC) action. This suit, filed against Taiwanese manufacturer APEX and its US distributor Medical Depot, seeks to have other devices alleged to infringe its patents banned from import into the US.

Medical Depot last week filed patents with the ITC revealing it is prepared to make a formal decree to stop importing and selling the APEX devices named in the suit, ResMed added.

“ResMed has built its unique market differentiation by investing in superior technology and medical science-driven innovation for sleep-disordered breathing therapy,” ResMed global general counsel and chief administrative officer David Pendarvis said.

“We will continue to defend our proprietary technology by enforcing our patents.”

ResMed this week launched an online tool to help sleep-disordered breathing patients monitor and track their progress, as well as a new positive airway pressure mask.

ResMed shares were trading 1.03% lower at $4.81 as of around 12.30 pm on Friday.

Related News

Simulated microgravity affects sleep, physiological rhythms

The simulated effects of microgravity significantly affect rhythmicity and sleep in humans, which...

Hybrid insulin pumps work well for type 1 diabetes

Advanced hybrid closed loop (AHCL) insulin pumps are designed to constantly measure blood sugar...

3D-printed films provide targeted liver cancer treatment

Researchers have created drug-loaded, 3D-printed films that kill more than 80% of liver cancer...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd